国内肿瘤领域药物经济学文献分析与评价  

System analysis and evaluation of pharmacoeconomic literatures of cancer published in China

作　　者：范丽萍[1,2] 焦园园[1] 郭子寒 张艳华[1] 

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [2]北京大学医学部药事管理与临床药学系,北京100191

出　　处：《中国临床药学杂志》2016年第3期175-178,共4页Chinese Journal of Clinical Pharmacy

摘　　要：目的分析和评价近几年来国内肿瘤领域药物经济学研究的文献质量,了解国内抗肿瘤药物经济学研究现状。方法检索2010-2014年在专业学术期刊发表的相关研究文献,根据药物经济学评价研究质量评价标准,评价纳入研究质量。结果共纳入药物经济学文献53篇,研究者多以药剂师为主,大部分无经费支持,期刊分布广泛,对比方案多以化疗方案为主,主要采用回顾性研究和成本效果分析,多以直接医疗成本作为成本指标,对药费进行单纯性敏感度分析。结论这些文献的研究内容符合临床需求,但缺乏足够的重视,文章质量有待进一步提高,主要表现在缺乏明确的评价角度、成本范围过窄、贴现问题易被忽略、研究设计方法有待提高和敏感性分析方法单一等方面。AIM To analyze and evaluate the quality of pharmacoeconomic literatures of cancer published in China, and understand the status of pharmacoeconomic evaluation studies. METHODS Pharmacoeconomic evaluation literatures published on domestic professional journals from 2010 to 2014 were researched. According to pharmacoeconomic evaluation criteria, the quality of included studies was evaluated. RESULTS There were 53 literatures included, the researchers were mainly pharmacists; most of researchers had no funding; the journals were widely dispersed; chemotherapy regimens were commonly used; retrospective study and cost-effectiveness analysis were commonly used; most of literatures took direct medical costs as cost indicators and carried out sensitivity analysis on the drug prices. CONCLUSION The contents of literatures conform to the clinical demand, but lack enough attention, and the quality of which overall is low; especially the perspective of most studies is not clear; the scope of the cost is too narrow ; the discount issue is easily ignored; design of study should be improved; and sensitivity analysis is single.

关 键 词：文献 药物经济学 恶性肿瘤 

分 类 号：R979.1[医药卫生—药品]